This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Chiasson and colleagues¹ claimed to have found an effect of acarbose on the risk of cardiovascular events in patients with IGT. These results are based on the evaluation of the so-called "modified" intent-to-treat (ITT) population, which excluded 61 originally randomized patients, most for lack of valid postrandomization data. It would be of interest to know how many cardiac events occurred in this entire cohort. However, outcome information about the original study group consisting of 714 patients in the acarbose group and 715 in the placebo group was previously available as "safety data" on the trial sponsor's study Web site and is now available at http://www.di-em.de/data/STOPNIDDM_table1.pdf. According to these data, cardiovascular events were similarly distributed between the original intervention and control group: in total 33 and 39 patients had at least one event.

In addition, it would be of interest to know why some end points—ie, . . . [Full Text of this Article]

Thomas Kaiser; Peter T. Sawicki, MD, PhD
Institute for Evidence-Based Medicine
St Franziskus Hospital Cologne
Cologne, Germany

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Julian H. Rosenthal
JAMA. 2003;290(23):3066.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Claude M. Bridges
JAMA. 2003;290(23):3066-3067.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
José-Miguel González-Clemente, Emilio Ortega-Martínez de Victoria, Olga Giménez-Palop, and Dídac Mauricio
JAMA. 2003;290(23):3067.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance—Reply
Jean-Louis Chiasson, Robert G. Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, and Markku Laakso
JAMA. 2003;290(23):3067-3069.
EXTRACT | FULL TEXT  

Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial
Jean-Louis Chiasson, Robert G. Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, and Markku Laakso
JAMA. 2003;290(4):486-494.
ABSTRACT | FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2981-2997.
ABSTRACT | FULL TEXT